Cargando…

Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation

Camellia nitidissima Chi (CNC) is a traditional Chinese medicine (TCM) with anticancer property. However, its underlying mechanisms of anti-colon cancer (CC) remain unknown. Therefore, a systematic approach is proposed in the present study to elucidate the anticancer mechanisms of CNC based on netwo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yiwei, Hao, Erwei, Zhang, Fan, Du, Zhengcai, Xie, Jinling, Chen, Feng, Yu, Chunlin, Hou, Xiaotao, Deng, Jiagang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413042/
https://www.ncbi.nlm.nih.gov/pubmed/34484402
http://dx.doi.org/10.1155/2021/7169211
_version_ 1783747577324240896
author Chen, Yiwei
Hao, Erwei
Zhang, Fan
Du, Zhengcai
Xie, Jinling
Chen, Feng
Yu, Chunlin
Hou, Xiaotao
Deng, Jiagang
author_facet Chen, Yiwei
Hao, Erwei
Zhang, Fan
Du, Zhengcai
Xie, Jinling
Chen, Feng
Yu, Chunlin
Hou, Xiaotao
Deng, Jiagang
author_sort Chen, Yiwei
collection PubMed
description Camellia nitidissima Chi (CNC) is a traditional Chinese medicine (TCM) with anticancer property. However, its underlying mechanisms of anti-colon cancer (CC) remain unknown. Therefore, a systematic approach is proposed in the present study to elucidate the anticancer mechanisms of CNC based on network pharmacology and experimental validation. Initially, the potential active ingredients of CNC were verified via the TCMSP database based on the oral bioavailability (OB) and drug-likeness (DL) terms. Hub targets of CNC were acquired from SwissTarget prediction and TCMSP databases, and target genes related to CC were gathered from GeneCards and OMIM databases. Cytoscape was used to establish the compound-target networks. Next, the hub target genes collected from the CNC and CC were parsed via GO and KEGG analysis. Results of GO and KEGG analysis reveal that quercetin and luteolin in CNC, VEGFA and AKT1 targets, and PI3K-Akt pathway were associated with the suppression of CC. Besides, the result of molecular docking unveils that VEGFA demonstrates the most powerful binding affinity among the binding outcomes. This finding was successfully validated using in vitro HCT116 cell model experiment. In conclusion, this study proved the usefulness of integrating network pharmacology with in vitro experiments in the elucidation of underlying molecular mechanisms of TCM.
format Online
Article
Text
id pubmed-8413042
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-84130422021-09-03 Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation Chen, Yiwei Hao, Erwei Zhang, Fan Du, Zhengcai Xie, Jinling Chen, Feng Yu, Chunlin Hou, Xiaotao Deng, Jiagang Evid Based Complement Alternat Med Research Article Camellia nitidissima Chi (CNC) is a traditional Chinese medicine (TCM) with anticancer property. However, its underlying mechanisms of anti-colon cancer (CC) remain unknown. Therefore, a systematic approach is proposed in the present study to elucidate the anticancer mechanisms of CNC based on network pharmacology and experimental validation. Initially, the potential active ingredients of CNC were verified via the TCMSP database based on the oral bioavailability (OB) and drug-likeness (DL) terms. Hub targets of CNC were acquired from SwissTarget prediction and TCMSP databases, and target genes related to CC were gathered from GeneCards and OMIM databases. Cytoscape was used to establish the compound-target networks. Next, the hub target genes collected from the CNC and CC were parsed via GO and KEGG analysis. Results of GO and KEGG analysis reveal that quercetin and luteolin in CNC, VEGFA and AKT1 targets, and PI3K-Akt pathway were associated with the suppression of CC. Besides, the result of molecular docking unveils that VEGFA demonstrates the most powerful binding affinity among the binding outcomes. This finding was successfully validated using in vitro HCT116 cell model experiment. In conclusion, this study proved the usefulness of integrating network pharmacology with in vitro experiments in the elucidation of underlying molecular mechanisms of TCM. Hindawi 2021-08-26 /pmc/articles/PMC8413042/ /pubmed/34484402 http://dx.doi.org/10.1155/2021/7169211 Text en Copyright © 2021 Yiwei Chen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chen, Yiwei
Hao, Erwei
Zhang, Fan
Du, Zhengcai
Xie, Jinling
Chen, Feng
Yu, Chunlin
Hou, Xiaotao
Deng, Jiagang
Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation
title Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation
title_full Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation
title_fullStr Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation
title_full_unstemmed Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation
title_short Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation
title_sort identifying active compounds and mechanism of camellia nitidissima chi on anti-colon cancer by network pharmacology and experimental validation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413042/
https://www.ncbi.nlm.nih.gov/pubmed/34484402
http://dx.doi.org/10.1155/2021/7169211
work_keys_str_mv AT chenyiwei identifyingactivecompoundsandmechanismofcamellianitidissimachionanticoloncancerbynetworkpharmacologyandexperimentalvalidation
AT haoerwei identifyingactivecompoundsandmechanismofcamellianitidissimachionanticoloncancerbynetworkpharmacologyandexperimentalvalidation
AT zhangfan identifyingactivecompoundsandmechanismofcamellianitidissimachionanticoloncancerbynetworkpharmacologyandexperimentalvalidation
AT duzhengcai identifyingactivecompoundsandmechanismofcamellianitidissimachionanticoloncancerbynetworkpharmacologyandexperimentalvalidation
AT xiejinling identifyingactivecompoundsandmechanismofcamellianitidissimachionanticoloncancerbynetworkpharmacologyandexperimentalvalidation
AT chenfeng identifyingactivecompoundsandmechanismofcamellianitidissimachionanticoloncancerbynetworkpharmacologyandexperimentalvalidation
AT yuchunlin identifyingactivecompoundsandmechanismofcamellianitidissimachionanticoloncancerbynetworkpharmacologyandexperimentalvalidation
AT houxiaotao identifyingactivecompoundsandmechanismofcamellianitidissimachionanticoloncancerbynetworkpharmacologyandexperimentalvalidation
AT dengjiagang identifyingactivecompoundsandmechanismofcamellianitidissimachionanticoloncancerbynetworkpharmacologyandexperimentalvalidation